These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36837928)

  • 41. Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol.
    Liu Y
    Heliyon; 2023 Mar; 9(3):e13853. PubMed ID: 36845041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Series of Adenosine Analogs as the First Efficacious Anti-SARS-CoV-2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research Study.
    Rabie AM; Abdalla M
    ChemistrySelect; 2022 Dec; 7(46):e202201912. PubMed ID: 36718467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
    Pandey K; Acharya A; Pal D; Jain P; Singh K; Durden DL; Kutateladze TG; Deshpande AJ; Byrareddy SN
    Antiviral Res; 2024 Jul; 227():105904. PubMed ID: 38729306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.
    Zou R; Peng L; Shu D; Zhao L; Lan J; Tan G; Peng J; Yang X; Liu M; Zhang C; Yuan J; Wang H; Li S; Lu H; Zhong W; Liu Y
    Front Pharmacol; 2022; 13():939573. PubMed ID: 35784723
    [No Abstract]   [Full Text] [Related]  

  • 45. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
    Zhou S; Hill CS; Sarkar S; Tse LV; Woodburn BMD; Schinazi RF; Sheahan TP; Baric RS; Heise MT; Swanstrom R
    J Infect Dis; 2021 Aug; 224(3):415-419. PubMed ID: 33961695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.
    Abdalla M; Rabie AM
    Comput Biol Chem; 2023 Jun; 104():107768. PubMed ID: 36842392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.
    Grimes SL; Choi YJ; Banerjee A; Small G; Anderson-Daniels J; Gribble J; Pruijssers AJ; Agostini ML; Abu-Shmais A; Lu X; Darst SA; Campbell E; Denison MR
    mBio; 2023 Aug; 14(4):e0106023. PubMed ID: 37338298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
    Arribas JR; Bhagani S; Lobo SM; Khaertynova I; Mateu L; Fishchuk R; Park WY; Hussein K; Kim SW; Ghosn J; Brown ML; Zhang Y; Gao W; Assaid C; Grobler JA; Strizki J; Vesnesky M; Paschke A; Butterton JR; De Anda C
    NEJM Evid; 2022 Feb; 1(2):EVIDoa2100044. PubMed ID: 38319178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis.
    Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M
    APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir "S-217622": A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species.
    Eltayb WA; Abdalla M; Rabie AM
    ACS Omega; 2023 Feb; 8(6):5234-5246. PubMed ID: 36798145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
    Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
    Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
    Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing.
    Miranda JA; McKinzie PB; Dobrovolsky VN; Revollo JR
    Environ Mol Mutagen; 2022 Aug; 63(7):320-328. PubMed ID: 36181379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro.
    Liu D; Leung KY; Lam HY; Zhang R; Fan Y; Xie X; Chan KH; Hung IF
    Virus Res; 2024 Jul; 345():199371. PubMed ID: 38621598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Nanopore Based Molnupiravir Sensor.
    Jia W; Hu C; Wang Y; Zhang P; Chen HY; Huang S
    ACS Sens; 2022 May; 7(5):1564-1571. PubMed ID: 35427117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
    De Vito A; Colpani A; Bitti A; Zauli B; Meloni MC; Fois M; Denti L; Bacciu S; Marcia C; Maida I; Babudieri S; Madeddu G
    J Med Virol; 2022 Nov; 94(11):5582-5588. PubMed ID: 35855627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic developments for SARS-CoV-2 infection-Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice.
    Săndulescu O; Apostolescu CG; Preoțescu LL; Streinu-Cercel A; Săndulescu M
    Front Microbiol; 2023; 14():1132501. PubMed ID: 36937282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study.
    Fountain-Jones NM; Vanhaeften R; Williamson J; Maskell J; Chua IJ; Charleston M; Cooley L
    Lancet Microbe; 2024 May; 5(5):e452-e458. PubMed ID: 38527471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.